Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SD-254
- Development stage
- Unknown
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SD-254 is a deuterium-substituted analog of venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), designed to improve pharmacokinetics by slowing metabolism through the kinetic isotope effect. Developed initially by Auspex Pharmaceuticals (later acquired by Teva), it demonstrated in Phase I trials a metabolism rate half that of venlafaxine, resulting in longer persistence at effective levels in the body and potentially fewer side effects.[1][5][11] Primarily targeted for major depressive disorder, it also showed promise for neuropathic pain, an indication not formally pursued with venlafaxine.[1][11]
- Other names
- deuterated venlafaxine
02
Targets
NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on SD-254.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SD-254.